Silexion Q2 net loss widens to $3.6M; Phase 2/3 trial initiated

Silexion Therapeutics Corp

Q2 net loss $3.6M vs $2.5M YoY; R&D up 120% to $2.2M on trial prep.
Six-month net loss $6.3M vs $4.2M; cash $2.2M at June 30, down from $6.0M.
Closed Aug 13 public offering gross $2.5M, net $2.1M; equity est. $3.2M, restoring Nasdaq compliance.
Phase 2/3 SIL204 trial initiated July 29 at Tel Aviv Sourasky; approvals from Germany BfArM and Israel.
1-for-10 reverse split May 28, 2026; preclinical data supports immune-sensitization across 4 KRAS mutations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.